Asia-Pacific Gene Therapy Market Set to Soar at 20% Growth
Gene Therapy Market Set to Expand to USD 29–55 Billion by 2033–2034 The Gene Therapy Market , valued at approximately USD 8–9 billion in 2024, is projected to grow at a compound annual growth rate (CAGR) of 18–20%, reaching between USD 29 and 55 billion by 2033–34. This dynamic expansion is driven by a growing pipeline of oncology and rare disease therapies, breakthroughs in vector technology, precision medicine tools, and increasing regulatory approvals. To Get Free Sample Report: https://www.datamintelligence.com/download-sample/gene-therapy-market Key Drivers & Opportunities 1. Oncology & Rare Diseases Lead Adoption Oncology remains the strongest therapeutic segment, with more than 25% CAGR. Gene therapies targeting rare genetic disorders such as spinal muscular atrophy, hemophilia, sickle cell disease, macular degeneration, and epidermolysis bullosa are emerging from clinical pipelines into market launches. Recent approvals include Hemgenix, Roctavian, Beqvez, and topical ...